Search results
Results from the WOW.Com Content Network
Medicare covers treatment and services for bladder cancer; however, you may still have significant out-of-pocket costs depending on factors like recommended treatment or the stage of your cancer.
The five-year survival rate for bladder cancer is 97% if it’s treated at its earliest and 71% if it’s treated before it spreads beyond the bladder. But in order to treat it early, it’s ...
Rik Bryan, professor in urothelial cancer research and director of the Bladder Cancer Research Centre at the University of Birmingham said the standard initial treatment pathway for bladder cancer ...
Ureter cancer rarely causes problems in the early stages, but as the cancer progresses, there are often side effects. [5] Symptoms of ureteral cancer may include "blood in the urine (); diminished urine stream and straining to void (caused by urethral stricture); frequent urination and increased nighttime urination (); hardening of tissue in the perineum, labia, or penis; itching; incontinence ...
Surgical treatment of LUTS can include: Ablation procedures – used in treating both bladder tumours [22] and bladder outlet obstruction, such as prostate conditions. [23] Bladder-neck incision (BNI) Removal of the prostate – open, robotic, and endoscopic techniques are used. Stenting of the prostate [24] and urethra.
The treatment of genitourinary cancer is managed by either a urologist or an oncologist, depending on the treatment type (surgical or medical). Most urologic oncologists in Western countries use minimally invasive techniques (laparoscopy or endourology, robotic-assisted surgery) to manage urologic cancers amenable to surgical management.
A new combination of cancer medications has been shown in research to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard ...
The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.